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Abstract
Background: Fusion of the MOZ and TIF2 genes by an inv (8) (p11q13) translocation has been
identified in patients with acute mixed-lineage leukemia. Characterization of the molecular
structure of the MOZ-TIF2 fusion protein suggested that the fusion protein would effect on nuclear
receptor signaling.
Results: A series of deletions from the N-terminus of the MOZ-TIF2 fusion protein demonstrated
that the MOZ portion is essential for nuclear localization of the fusion protein. Transient
expression of MOZ-TIF2 dramatically decreased both basal and estradiol inducible reporter gene
activity in an estrogen receptor element (ERE) driven luciferase reporter system and decreased
androgen-inducible reporter gene activity in an androgen receptor element (ARE) luciferase
reporter system. Deletions in the MOZ portion of the MOZ-TIF2 fusion protein reduced the
suppression in the ER reporter system. Stable expression of MOZ-TIF2 inhibited retinoic acid (RA)
inducible endogenous CD11b and C/EBPβ gene response. The suppression of the reporter systems
was released with either a CID domain deletion or with mutations of leucine-rich repeats in the
TIF2 portion of MOZ-TIF2. The co-expression of TIF2, but not CBP, with MOZ-TIF2 partially
restored the inhibition of the reporter systems. In addition, analysis of protein interactions
demonstrated MOZ-TIF2 interaction with the C-terminus of CBP through both the MOZ and TIF2
portions of the fusion protein.
Conclusion:  MOZ-TIF2 inhibited nuclear receptor-mediated gene response by aberrant
recruitment of CBP and both the MOZ and TIF2 portions are required for this inhibition.
Background
Chromosomal translocations resulting in MOZ-(mono-
cytic leukemia zinc finger protein)-TIF2 (transcriptional
intermediary factor 2) fusions occur in acute myelogenous
leukemia and most commonly have been seen with AML
of the French-American-British phenotype of M4/M5 sub-
type. The MOZ-TIF2 fusion protein consists of the N-ter-
minus of MOZ and the C-terminus of TIF2. Patients with
these translocations often exhibit rapid progression and
poor response to therapy. Various translocations involv-
ing MOZ have been described such as MOZ-CBP (cAMP-
response element binding protein t(8;16)(p11;p13),
MOZ-P300 t(8;22)(p11;q13), and MOZ-TIF2
(inv(8)(p11q13). In a pediatric patient with therapy-
related myelodysplastic syndrome a MOZ translocation
was found between t(2;8)(p23;p11) [1-8]. In addition, a
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MOZ homologous protein, MORF (monocytic leukemia
zinc finger protein-related factor) has been found fused to
CBP via t(10;16)(q22;p13) in patients with AML and ther-
apy-related myelodysplastic syndromes [9-11].
MOZ is a histone acetyltransferase (HAT) [12,13] and
plays a role in maintenance of hematopoietic stem cells
[14,15]. MOZ also functions as a transcription regulator
to activate RUNX1 and RUNX2-mediated transcription
through protein-protein interactions. Co-expression of
RUNX1 and MOZ can synergistically activate the MIP-1
alpha promoter through a proximal RUNX binding site
[16,17]. The N- and C-termini of MOZ have different
functions with the N-terminus responsible for transcrip-
tion repression and the C-terminus for transcription acti-
vation. The MOZ-CBP fusion blocks RUNX1-mediated
transcription. We have previously identified by yeast two-
hybrid analysis and co-immunoprecipitation two human
chromatin assembly factors, the p150 subunit of chroma-
tin assembly factor (CAF) and anti-silencing function 1b
(ASF1b), that interact with MOZ and the MOZ portion of
the MOZ-TIF2 protein [18]. In zebrafish, MOZ through its
crucial histone acetyltransferase activity regulated Hox
expression. A MOZ mutation caused a late defect in facial
motor-neuron migration and led to a abnormality in pha-
ryngeal arch developmental [19].
TIF2 belongs to the p160 protein family which also
includes SRC-1 (Steroid receptor coactivator), TIF2/
GRIP1/SRC-2, and pCIP/ACTR/AIB-1/RAC-3/TRAM-1/
SRC-3. The functions of the p160 family have been well
reviewed [20-24]. The molecular structure of TIF2 demon-
strates several functional domains including a PAS/bHLH
domain, a receptor interaction region, and two activation
domains (AD) [25-28]. In nuclear receptor signaling, TIF2
binds to nuclear receptors predominately through its
nuclear receptor interacting domain (NID) [29,30] and
recruits the transcriptional co-activators CBP/p300
through CBP interaction domain (CID/AD1) [27,31] and
CARM-1, an arginine methytransferase, through AD2 [32-
35]. As a consequence, acetylation and methylation in his-
tone H3 and the KIX domain of CBP/p300 activates the
promoter and facilitates the basal transcriptional machin-
ery. TIF2 knock-out mice displayed significantly reduced
fertility and abnormalities in white adipose tissue and
energy metabolism [36-38].
The expression of MOZ-TIF2 in a mouse model resulted in
acute myelogenous leukemia (AML) and blocked the dif-
ferentiation of stem cells to hematopoietic progenitors
[39,40]. The deletion of the CID in the TIF2 partner of
MOZ-TIF2 abolished the leukemogenesis and blocked the
inhibition by MOZ-TIF2 of RAR, PPAR, and p53-mediated
transcription [41]. MOZ-TIF2 also altered cofactor recruit-
ment and histone modification at the RARbeta2 promoter
[42]. In this study, we demonstrate that the MOZ portion
of the MOZ-TIF2 fusion protein is essential for nuclear
localization of MOZ-TIF2 and describe MOZ-TIF2 repres-
sion of transcriptional activation by ER and AR. This inhi-
bition depended not only on the CID domain in TIF2
portion but also on multiple domains in the MOZ por-
tion. The forced expression of TIF2, but not CBP, could
reverse the inhibition. Stable expression of MOZ-TIF2
altered the retinoid acid (RA)-mediated endogenous gene
responses.
Results
The structure of MOZ-TIF2 and expression of the fusion 
gene
More than 5 cases of AML of the M4/M5 subtype have
been reported with chromosome translocation of inv (8)
(p11q13). The fusion in the patient at our institution
occurred at nucleotide position 3744 in the MOZ coding
region and nucleotide position 2974 in the TIF2 coding
region. The schematic structure of MOZ-TIF2 is shown in
Figure 1A. The fusion protein contains from the MOZ
moiety the PHD zinc finger domain, the MYST domain,
and a region rich in acidic amino acids and from the TIF2
portion the CID domain, the Q-rich region, and the AD2
domain. After transient transfection with the MOZ-TIF2
expression plasmid or transduction with a retrovirus
expressing the MOZ-TIF2 fusion (Figure 1B) expression of
MOZ-TIF2 RNA was seen in HEK 293, K562, and NIH3T3
cells. Using an EGFP-tagged MOZ-TIF2 construct expres-
sion of the fusion protein was detected by western analysis
(Figure 1C) and could be seen localized to the nuclei of
transfected cells (Figure 1D). Examination of the protein
sequence of the fusion protein suggests that in MOZ-TIF2
there are two potential nuclear localization signals located
between amino acids 83–180 and 909–1107. However,
MOZ-TIF2 with deletion of either amino acid 41–738
(Figure 2, third row) or 909–1107 (Figure 2, fourth row)
still localized to the nucleus. Even deletion of both poten-
tial nuclear localization regions could not exclude the
MOZ-TIF2 completely from the nucleus (Figure 2, fifth
row). Only deletion of a considerable amount of the MOZ
portion caused the protein localization to shift from
nucleus to cytoplasm (Figure 2, sixth row).
MOZ-TIF2 affects the transcription activation of ER and 
AR
TIF2 is a co-activator of nuclear hormone receptors and its
two activation domains, CID and AD2, are retained in the
MOZ-TIF2 fusion. To determine if the MOZ-TIF2 fusion
protein alters the co-activator function of wild type TIF2 in
nuclear receptor mediated transcription activation we
used a luciferase reporter system driven either by a pro-
moter containing the estrogen receptor binding element
(ERE) or the androgen receptor binding element (ARE).
Co-transfection of the luciferase reporter ERE plasmidMolecular Cancer 2007, 6:51 http://www.molecular-cancer.com/content/6/1/51
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Schematic structure of the MOZ-TIF2 fusion gene and expression and localization of MOZ-TIF2 Figure 1
Schematic structure of the MOZ-TIF2 fusion gene and expression and localization of MOZ-TIF2. A. Schematic 
representation of human MOZ, human TIF2, the MOZ-TIF2 fusion protein, and CBP. The break point for MOZ is amino acid 
1117 and for TIF2 is amino acid 939. B. Expression of MOZ-TIF2 RNA. Left panel, schematic representation of PCR primers 
(thick arrows) in fusion region of MOZ-TIF2. F, forward primer and R, reverse primer. Right panel, RNA expression of MOZ-
TIF2 as detected by RT-PCR in transduced or transfected cells. Lane 1, NIH-3T3 cells transduced with retrovirus control. Lane 
2, NIH-3T3 cells transduced with a retrovirus expressing MOZ-TIF2 fusion protein. Lane 3 and Lane 4, HEK 293 cells (Lane 3) 
and K562 cells (Lane 4) transfected with pcDNA3.1-MOZ-TIF2. Lane 5, K562 cells transfected with pcDNA3.1 alone. Lane M, 
molecular weight markers. C. Expression of EGFP-tagged MOZ, MOZ-TIF2, and TIF2 proteins in HEK293 cells. Cells were 
transiently transfected with various pEGFP fusion constructs, cell lysates extracted 36 hours later and separated by SDS-PAGE 
(4–20% polyacrylamide). Western blot analysis was performed to detect EGFP tagged proteins of MOZ, MOZ-TIF2, and TIF2 
with mouse monoclonal antibody to EGFP. MW, molecule markers in kilodaltons (kD). D. The localization of EGFP-tagged 
MOZ-TIF2 in HEK 293, CV-1, and K562 cells with the nuclei stained with DAPI.
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The MOZ portion of MOZ-TIF2 is essential for nuclear localization of MOZ-TIF2 Figure 2
The MOZ portion of MOZ-TIF2 is essential for nuclear localization of MOZ-TIF2. EGFP fusions with MOZ-TIF2 
fragments were transiently transfected into HEK 293 cells. After 24 hour, localization of EGFP fusion protein in HEK 293 cells 
was observed by confocal microscopy. Nuclei were stained in live HEK 293 cells with DRAQ5™ (AXXORA, LLC, San Diego, 
CA).
EFGFP-FUSION                        DRAQ5                             MERGE        
MOZTIF2 1-124
MOZITF2 1-315
MOZTIF2 1-1644
del 41-738
MOZTIF2 1-1644
del 14-1107
MOZTIF2 1-1644
del 83-180/909-1107
MOZTIF2 1-1644
del 909-1107Molecular Cancer 2007, 6:51 http://www.molecular-cancer.com/content/6/1/51
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with MOZ-TIF2 into CV-1 cells caused a significant
decrease in luciferase activity both in basal and estrogen
induced conditions (Figure 3A) compared to the co-trans-
fection with wild type MOZ, TIF2, or vector alone. The
induction by estrogen in MOZ-TIF2 was inhibited by 64
% compared to that in pcDNA3 control. The inhibition of
AR-activated transcription by MOZ-TIF2 was also demon-
strated with the full length PSA promoter/enhancer (PL)
that has multiple AREs and with a short promoter (PC)
that has two AREs. Compared to MOZ, TIF2, and vector
alone, there was a significant suppression by MOZ-TIF2
either with the PL PSA promoter (Figure 3B) or the PC PSA
promoter (Figure 3C).
The leucine-rich repeats in the CID of TIF2 determines the 
inhibition in transcription activation of ER and AR by 
MOZ-TIF2
The CID domain of the TIF2 protein is important to
recruit CBP/p300 into the nuclear receptor mediated tran-
scriptional complex to acetylate histone and non-histone
proteins and to promote transcription. However, as
shown above MOZ-TIF2 exhibited decreased ER and AR-
mediated transcription. To determine if altered recruit-
ment of CBP/p300 into the nuclear receptor mediated
transcriptional complex is responsible for inhibition of
transcription of the MOZ-TIF2 fusion protein, we exam-
ined the effects of deletion of the CID domain both in the
intact TIF2 as well as the MOZ-TIF2 fusion protein (Figure
4). Compared with the wild type MOZ-TIF2, the MOZ-
TIF2 with deleted CID exhibited increased transcription
activation of ER (Figure 4A) by 3.4 and 4.3 fold under
both basal and estrogen stimulated conditions, respec-
tively. In contrast, the deletion of CID in TIF2 reduced
estrogen induction by 1.4 fold compared to wild type TIF2
(Figure 4A). With AR-mediated transcription, the CID
deletion increased androgen induction by 6.7 fold com-
pared to intact MOZ-TIF2 (Figure 4B). These results sug-
gest that the CID in MOZ-TIF2 is necessary for inhibition
of ER and AR-mediated transcription activation and has
an opposite effect in the wild type TIF2.
We next mutated the two leucine-rich repeats PDDLL and
LLDQL in the CID domain of MOZ-TIF2 by mutating sev-
eral leucines to alanines in the region between amino
acids 1231 and 1270 (Figure 4C). The LLDQL repeat has
previously been demonstrated to be a CBP binding motif
[27] The mutation of two repeats significantly stimulated
both estrogen (Figure 4A) and androgen (Figure 4B), acti-
vated transcription compared to wild type MOZ-TIF2.
With the mutated MOZ-TIF2, ligand-stimulated transcrip-
tion increased approximately 4.2 fold for ER and 8.9 fold
for AR, respectively.
MOZ-TIF2 inhibits the transcriptional activation of ER and AR Figure 3
MOZ-TIF2 inhibits the transcriptional activation of ER and AR. A. 
MOZ-TIF2 (MT2) and ER activity. pVit-TKSL, an estrogen response element-
driven luciferase reporter plasmid was co-transfected into CV-1 cells with an 
estrogen receptor expression vector and pCDNA3.1-MOZ, pCDNA3.1-MOZ-
TIF2 (MT2), pCDNA3.1-TIF2 or vector alone. B and C. MOZ-TIF2 and AR activ-
ity. Two androgen response element-driven luciferase reporter systems were 
employed. B shows the effect of a plasmid that contains a full length PSA pro-
moter (PL) with multiple androgen response element sites and C shows the effect 
of a plasmid containing a minimum PSA promoter (PC) with only two androgen 
response elements. Both ARE-containing reporter plasmids were co-transfected 
with an androgen receptor expression vector and either pCDNA3.1-MOZ, 
pCDNA3.1-MOZTIF2 (MT2), pCDNA3.1-TIF2 or vector alone. 5α-dihydrotesto-
sterone (DHT) was added to a final concentration of 50 nM, the cells collected 
and luciferase activity measured as described above. Double or single stars repre-
sent a significant difference at P < 0.01 or P < 0.05 level respectively by the two 
tail Student T- test compared to the transfection with MOZ-TIF2 in the ligand 
added condition. Open bars, 50 nM estradiol (A) or DHT (B and C). Dark bars, 
no added estradiol (A) or DHT (B and C). The numbers on top of the open bars, 
i.e. added ligand, are the ratios of light units in presence of the ligand to light units 
in the absence of ligand. The percentage inhibition noted in the text was calcu-
lated from the percent of light units resulting from induction by estrogen in 
MOZ-TIF2 expressing cells compared to pcDNA-transfected control cells sub-
tracted from 100%.Molecular Cancer 2007, 6:51 http://www.molecular-cancer.com/content/6/1/51
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MOZ-TIF2-mediated repression of transcription can be 
partially restored by TIF2 but not CBP
CBP participates in many transcription events and may,
therefore, be simultaneously required by multiple path-
ways. An example of competition for CBP has been shown
for the hematopoietic Ets transcription factor Spi-B com-
peting for CBP with c-Myb [43]. In addition, forced
expression of CBP in a p53 deficient cell line, SaOS-2,
released the inhibition of p53-mediated transcription by
MOZ-TIF2 [41]. To determine if CBP was a limiting factor
leading to inhibition by MOZ-TIF2 of the transcriptional
activation of the ER or AR reporter constructs, MOZ-TIF2
was co-transfected with a plasmid expressing CBP. How-
ever, forced expression of CBP did not reverse the MOZ-
TIF2-mediated suppression of ER mediated transcription
(Figure 5A) nor of AR-mediated transcription (data not
shown), suggesting that CBP was not a limiting factor in
our experimental systems. In contrast, co-transfection of
TIF2 with MOZ-TIF2 reversed the inhibition of ER-medi-
ated transcription by MOZ-TIF2 (Figure 5B). Hence, the
relative deficiency in transcription co-factors contributes
to the inhibition of nuclear receptor-mediated transcrip-
tion by MOZ-TIF2. To address if the levels of transcription
cofactors could be limiting in vivo, we examined the RNA
expression of several transcription co-factors in leukemic
blasts and found significant decreases in RNA expression
of TIF2 and CBP in the cells of the patient with the MOZ-
TIF2 fusion compared to levels in leukemic blasts from
patients without the MOZ-TIF2 fusion (Figure 6).
MOZ-TIF2 interacts with CBP in the ER-mediated 
transcription complex
The above results suggest that an interaction between
MOZ-TIF2 and CBP could be essential for the inhibition
of ER and AR-mediated transcription by MOZ-TIF2. To
obtain direct evidence for the recruitment of CBP by the
MOZ-TIF2 fusion protein HEK293 cells were transfected
with His-tag MOZ and MOZ-TIF2 (Figure 7A, B, and 7C).
In these experiments CBP was co-precipitated both by
MOZ-TIF2 and interestingly by MOZ, too (Figure 7C).
Corrected for the expression of CBP (Figure 7B) and pre-
cipitated MOZ and MOZ-TIF2 (Figure 7A), the ratio of
CBP co-precipitating with MOZ and CBP co-precipitating
with MOZ-TIF2 was 2 to 1. Interestingly, p300, a CBP-like
histone acetylase was co-precipitated by wild type MOZ
and MOZ-TIF2 (data not shown). Furthermore, to dem-
onstrate the participation of MOZ-TIF2 in ER-mediated
transcription complex, HEK293 cells were transfected
with EGFP-tagged MOZ-TIF2 or TIF2 (Figure 7D). The
fusion proteins were then precipitated with anti-EGFP
antibody and the co-precipitation of ER was examined by
Western blot analysis using anti-ER antibody (Figure 7E).
Standardized to the levels of EGFP-MOZ-TIF2 and EGFP-
TIF2 (Figure 7A), the ratio of ER co-precipitating with
MOZ-TIF2 to ER co-precipitating with TIF2 was 1 to 1.7.
As further support for an interaction between MOZ and
CBP, we observed the expression and localization of
endogenous MOZ and CBP in HEK 293 cells (Figure 7F).
MOZ was co-localized with CBP in the nucleus through
G1-S-G2 stage (Figure 7F, top panel) but dissociated from
the chromosomes in metaphase (Figure 7F, middle panel)
only to re-associate with chromatin in cytokinesis at the
end of M stage (Figure 7F, bottom panel). A similar pat-
tern of co-localization between MOZ and CBP through
the cell cycle could also be demonstrated in HeLa cells
(data not shown).
Deletion of the CID domain and mutations in two leucine-rich repeats in the  CID domain of the TIF2 portion of MOZ-TIF2 released the inhibitory effect of  MOZ-TIF2 on the transcriptional activation of ER and AR in CV-1 cells Figure 4
Deletion of the CID domain and mutations in two leucine-rich 
repeats in the CID domain of the TIF2 portion of MOZ-TIF2 
released the inhibitory effect of MOZ-TIF2 on the transcriptional 
activation of ER and AR in CV-1 cells. A. ER signaling. pVit-TKSL was co-
transfected with an estrogen receptor expression plasmid (hER) into CV-1 
cells. B. AR signaling. The reporter plasmid PL was used as described in Figure 
3. Del CID: The CID domain was deleted from MOZ-TIF2 (MT2 delCID) 
(amino acids 1182–1312) and TIF2 (TF2 delCID) (amino acids 1002–1132). 
DBL : mutations were created in the leucine-repeat regions of CID of MOZ-
TIF2 (MT2DBL) and TIF2 (TF2 DBL) as shown in panel C. The letters in bold 
type in C represent the mutated amino acids. Open bars, 50 nM estradiol (A) 
or DHT (B). Dark bars, no added estradiol (A) or DHT (B). Double stars rep-
resent a significant difference at P < 0.01 by the two-tailed Student T- test 
compared to the transfection with MOZ-TIF2 in the ligand added condition. 
Solid circles represent a significant difference at P < 0.05 by two-tailed Student 
T- test compared to the transfection with TIF2 in the ligand added condition. 
The numbers on top of the open bars indicate the ratio of light units in the 
presence and absence of ligand as described in Figure 3. The fold increase 
given in the text was calculated as light units with the mutated MOZ-TIF2 
compared to the wild type MOZ-TIF2 in absence or presence of ligand and 
fold decrease was calculated as the light units with the wild type TIF2 com-
pared to the light units with the CID deleted TIF2.Molecular Cancer 2007, 6:51 http://www.molecular-cancer.com/content/6/1/51
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The MOZ portion of MOZ-TIF2 contributes to CBP 
binding and nuclear receptor-mediated transcription 
inhibition
As CBP co-immunoprecipitated with MOZ and MOZ-TIF2
we now investigated possible interactions of CBP with the
MOZ portion of MOZ-TIF2, In these experiments we per-
formed a cell-free GST pull down assay (Figure 8A, B, and
8C) using various fragments of MOZ-TIF2 labeled with
35S-methionine by in vitro translation. GST fusions with
two CBP fragments from the C-terminus of CBP were also
synthesized and purified. The CBP C-terminal domain
was included in these experiments based on the previous
demonstration that the C-terminus was important for the
interaction with p53, E1A, and E2F [44,45]. In these
assays a 35S-methionine labeled peptide consisting of
amino acids 1–759 of MOZ-TIF2, was pulled down by the
GST tagged C-terminal region of CBP (amino acids 1680
RNA expression in leukemic blasts from AML patients with  or without MOZ-TIF2 fusion Figure 6
RNA expression in leukemic blasts from AML 
patients with or without MOZ-TIF2 fusion. RNA was 
isolated from the leukemic blasts of 5 different patients. RNA 
was also isolated on three separate occasions from the 
leukemic blasts of the patient exhibiting the MOZ-TIF2 
fusion. RT-PCR was conducted as described in Experimental 
Procedures using the primers listed in Table 1. Shown are 
the results as relative amounts of RNA in the non-MOZ-TIF2 
leukemic blasts (clear bars) compared to the MOZ-TIF2 
blasts (shaded bars). Stars represent a significant difference at 
P < 0.05 by the two-tailed Student T-test comparing RNA 
levels in the blasts of the patients without the MOZ-TIF2 
fusion to the levels in the blasts with the MOZ-TIF2 fusion.
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MOZ-TIF2 inhibition of ER-mediated transcription was not  antagonized by increased expression of CBP and expression  of MOZ-TIF2 competed with wild type TIF2 in ER signaling Figure 5
MOZ-TIF2 inhibition of ER-mediated transcription 
was not antagonized by increased expression of CBP 
and expression of MOZ-TIF2 competed with wild 
type TIF2 in ER signaling. CV-1 cells were co-transfected 
with pVit-TKSL containing MOZ-TIF2 or MOZ-TIF2 plus 
CBP or TIF2. The cells were lysed and luciferase activity was 
measured as described after incubation of the transfected 
cells for 36 hours of cells with 50 nM estradiol. A. The 
forced expression of CBP does not antagonize MOZ-TIF2 
inhibition of ER-mediated transcription. B. The inhibition of 
ER-mediated transcription by MOZ-TIF2 was partially 
released by increased expression of wild type of TIF2. Open 
bars, the presence of 50 nM estradiol; dark bars, without 
estradiol. Double stars represent a significant difference at P 
< 0.01 by the two tailed Student T- test compared to the 
transfection with MOZ-TIF2 in the ligand added condition. 
Dark circles represent a significant difference at P < 0.05 
compared to the transfection with TIF2 alone in the ligand 
added condition. The numbers on top of the open bars indi-
cate the ratio of light units as described in Figure 3.
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MOZ-TIF2 participates in the ER activation complex as does TIF2 and interacts with CBP in vivo Figure 7
MOZ-TIF2 participates in the ER activation complex as does TIF2 and interacts with CBP in vivo. A, B, and C. 
For identification of the interaction between MOZ-TIF2 and CBP, HEK 293 cells were transiently transfected with His-tagged 
MOZ, MOZ-TIF2, and vector alone. After 36 hours, the cells were lysed and co-immunoprecipitation conducted by an anti 
His-tag antibody conjugated to agarose beads. The co-immunoprecipitated proteins were separated by SDS-PAGE and western 
analyses were performed with an anti-CBP antibody. The input represents 5% of the protein used in the co-immunoprecipita-
tion and was from cells transfected with MOZ-TIF2. A. Western blot showing MOZ and MOZ-TIF2 bound to the agarose 
beads. B. Transfected cells subjected to SDS-PAGE to demonstrate the presence of CBP in the transfected HEK293 cells. C. 
Western blot analysis to demonstrate CBP co-immunoprecipitating with MOZ and MOZ-TIF2. D and E. To determine the 
presence of MOZ-TIF2 in ER activation complexes, HEK 293 cells were transiently co-transfected with pEGFP-MOZ-TIF2 or 
pEGFP-TIF2 and with an expression plasmid for the estrogen receptor, RSV-hER. After the addition of 50 nM estradiol for 36 
hours, the cells were lysed and co-immunoprecipitation was performed with 500 µg protein using an anti-EGFP antibody. The 
co-immunoprecipitated proteins were subjected to 12% SDS-PAGE fractionation and ER was detected by western blot with 
anti-ER antibody. The input represents 5% of the protein used in the co-immunoprecipitation. D. The expression level of EGFP 
fusions in cells transfected with MOZ-TIF2 (GFP-MT2) and TIF2 (GFP-TIF2). E. The co-immunoprecipitation of ER by MOZ-
TIF2 or TIF2. Input 1 is from cells transfected with pEGFP-TIF2 and input 2 is from cells transfected with pEGFP-MOZ-TIF2. F. 
Co-localization between endogenous MOZ and CBP in HEK293 cells during the cell cycle. Top panel, co-localization of MOZ 
and CBP in the nucleus during G1-S-G2 stage. Middle panel, the co-localization disassociated from chromosomes during the 
metaphase. Bottom panel, the restoration of co-localization with chromatin.Molecular Cancer 2007, 6:51 http://www.molecular-cancer.com/content/6/1/51
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CBP interacts with multiple sites in the MOZ portion of MOZ-TIF2 Figure 8
CBP interacts with multiple sites in the MOZ portion of MOZ-TIF2. A. The MOZ portion (amino acids 1–759) of MOZ-TIF2 interacts with the C-terminus 
of CBP. As described in Experimental Procedures, a 35S-methionine labeled CBP fragment (amino acids 1680–2441) was incubated with the GST-MOZ-TIF2 fragment 
(amino acids 1–759) (MT2 1–759) and the reaction mixture absorbed to Sepharose 4B-GSH beads. After extensive washing the beads were treated with sample 
buffer, absorbed proteins separated on SDS-PAGE, and CBP fragments detected with radioautography. GST, the pull-down by GST tag peptide alone mixed with 
MT2 1–759. CBP 1680–2441, 10 % of the CBP 1680–2441 peptide input into the reaction. MT2 1–759, CBP absorbed to Sepharose-GSH beads through GST-MT2 
1–759 peptides. B. The MOZ portion of MOZ-TIF2 interacts with the CH3 domain of CBP. Three peptides-MOZ-TIF2 1–759, MOZ-TIF2 760–1644 (amino acids 
760–1644), and MOZ-TIF2 760–1644 with deleted CID domain (deleted amino acids 1183–1311)-were labeled with 35S-methionine by synthesis by in vitro transla-
tion. GST-CBP peptides (amino acids 1680–1892) were expressed in E. coli and purified by Glutathione Sepharose™ 4B beads. MOZ-TIF2 peptides and GST-CBP 
peptides were allowed to interact as described in Experimental Procedures and the proteins absorbed to GST-CBP beads were analyzed as described. Input was 10% 
of 35S-methionine labeled polypeptides used in the binding reaction. GST, the pull-down by GST peptide alone mixed with MOZ-TIF2 peptides. CBP 1680–1892, pull-
down by GST-CBP peptides (amino acids 1680–1892) incubated with 35S-methionine labeled MOZ-TIF2 1–759, MOZ-TIF2 760–1644, and MOZ-TIF2 760–1644 with 
deleted CID domain. Input-MT2 1–759, Input-MT2 760–1644, and Input-MT2 D 760–1644 are 10 % input of 35S-methionine labeled peptides of MOZ-TIF2 1–759, 
MOZ-TIF2 760–1644, and MOZ-TIF2 760–1644 with deleted CID domain used in the reaction. C. The PHD and MYST domains of the MOZ moiety in the fusion 
protein interact with the CH3 domain of CBP. The 35S-methionine labeled CH3 domain peptides of CBP were incubated with GST-MOZ peptides, absorbed to Glu-
tathione Sepharose™ beads, the absorbed proteins separated by SDS-PAGE, and subjected to radioautography. The input represents 10% of 35S-methionine labeled 
peptides used in the binding reaction. GST and input CBP 1680–1892 have the same meanings as described in A above. MT2 1–235, MT2 1–311, and MT2 523–759, 
peptides of the MOZ partner from amino acids 1–235, 1–311, and 523–759 respectively were used in the incubation with the CH3 domain of CBP. D. GST pull-
down analysis of CBP binding sites in MOZ partner of MOZ-TIF2. GST tagged C terminal of CBP(amino acids 1680–2441) were expressed in E. coli and purified by 
Glutathione Sepharose™ 4B beads. The expression plasmid with Xpress-tagged MOZ-TIF2 fragments was transfected into HEK 293 cells. After 36 hours whole cell 
extract was prepared and incubated with GST-tagged C terminal of CBP absorbed onto Glutathione-Sepharose beads. The Xpress-tagged MOZ-TIF2 fragments 
pulled down by GST-tagged C-terminal of CBP were detected with anti-Xpress antibody and are seen in lane 3. Lane 1 represents 5% of the input of expressed 
Xpress-tagged MOZ-TIF2 fragment. Lane 2, incubation of Xpress-tagged MOZ-TIF2 fragment with GST peptide alone. E. Deletion of CBP binding sites in MOZ por-
tion decreases the inhibition of the transcriptional activation of ER by MOZ-TIF2. As described in Figure 3, an estrogen response element-driven luciferase reporter 
plasmid was co-transfected into CV-1 cells with an estrogen receptor expression vector and pCDNA3.1 plasmid inserted with MOZ-TIF2 fragments or vector alone. 
The relative luciferase activity in light units is shown after correction of transfection efficiency by measurement of beta galactosidase activity. Double stars represents 
a significant difference at P < 0.01 level respectively by two tail student T- test compared to the transfection with MOZ-TIF2 in the ligand added condition. Open bar, 
50 nM estradiol. Dark bar, no added estradiol. The numbers on top of the open bars indicate the ratio of light units in the presence and absence of ligand as 
described in Figure 3.
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to 2441) (Figure 8A). The binding site of MOZ 1–759 to
the C-terminus of CBP was further localized to the CH3
domain of CBP (amino acids 1680 to 1892). The TIF2
portion of MOZ-TIF2 fusion (amino acids 760–1644)
also bound to the CH3 domain of CBP but required the
CID domain of TIF2 (Figure 8B). Binding between the
MOZ portion of MOZ-TIF2 and CBP showed that frag-
ment containing the PHD domain (amino acids 1–253)
and a fragment containing the MYST domain (amino
acids 523–759) bound to a CBP fragment containing the
CH3 domain (amino acids 1860–1892) (Figure 8C). To
further demonstrate the multiple binding sites of CBP in
MOZ portion, we examined the binding of C-terminal of
CBP with region-specific deleted MOZ-TIF2 protein by
pull down assay and verified that multiple CBP binding
sites existed in the MOZ portion of the MOZ-TIF2 fusion
protein (Figure 8D). Deletion of both the PHD and MYST
domains (Figure 8D, MT2 1–907 del 193–346/486/764)
could not abolish the binding of the MOZ portion frag-
ment to CBP; however, deletion of almost the entire MOZ
portion and the CID domain in TIF2 portion blocked the
binding of MOZ-TIF2 to CBP (Figure 8D, MT1–1644 del
82–892/1182–1302). To address if multiple CBP binding
sites are functionally important, we tested the ER-medi-
ated transcription activity of MOZ-TIF2 proteins with a
region specific deletion in MOZ portion (Figure 8E).
These results showed that multiple CBP binding sites in
the MOZ portion are necessary for MOZ-TIF2 to affect ER
transcription and deletion of any of these sites could par-
tially release the transcription inhibition effects seen with
MOZ-TIF2.
MOZ-TIF2 inhibits expression of endogenous RA response 
genes in U937 cells
To support our findings with the reporter systems, we
examined the inhibition of endogenous RA response
genes in U937 cells with stable expression of MOZ-TIF2.
The expression level of MOZ-TIF2 RNA in two established
clones, MT2-1 and MT2-1, was similar (MT2-1) to or
lower (MT2-2) than that seen in the patient's leukemic
blasts (Figure 9A). Expression of two well-known RA
response genes, C/EBPβ (Figure 9B and 9C) and CD11b
(Figure 9D and 9E) were examined in the two U937
clones at the RNA (Figure 9C and 9D) and protein level
(Figure 9B and 9C). Induction of C/EBPβ RNA by RA was
inhibited by 86% in clone MT2-1 and 40% in clone MT2-
2 (Figure 9C). and C/EBPβ protein expression after RA
treatment was reduced by 90% in MT2-1 and 54% in
MT2-2 (Figure 9B), respectively, compared to that of con-
trol cells. Similarly, induction of CD11b RNA by RA was
decreased by 60% in both MT2-1 and MT2-2 clones (Fig-
ure 9D). A flow cytometry analysis showed that the
number of CD11b positive cells in the MT2-2 clone of
MOZ-TIF2 expressing U937 cells was less than 50 % of
control cells (Figure 9E). MOZ-TIF2 with deletions either
Stable expression of MOZ-TIF2 in U937 cells down-regulates retinoic acid (RA)- mediated induction of CD11b and C/EBPβ genes Figure 9
Stable expression of MOZ-TIF2 in U937 cells down-regulates retinoic acid 
(RA)-mediated induction of CD11b and C/EBPβ genes. A. Relative expres-
sion of MOZ-TIF2 mRNA in stably transfected U937 cells and leukemia patient's 
blast. U937 cells were transfected with the pcDNA3.1 plasmid carrying the full length 
MOZ-TIF2 cDNA. After selection with G418, two clones were established, MT2-1 
and MT2-2, and expression of MOZ-TIF2 (MT2) mRNA was examined by RT-PCR in 
the two clones, in the patient's blasts, and in U937 cells stably transfected with vector 
alone. B. Expression of C/EBPβ protein in RA treated U937 cells. Cells were treated 
with 1 µM RA for 72 hours, whole cell protein extracted with RIPA buffer, and pro-
teins fractionated by SDS-PAGE. Western blot analyses were conducted with anti-C/
EBPβ antibody. Top panel, western blot of C/EBPβ and β-tubulin. Bottom panel, rela-
tive level of C/EBPβ protein in control and MOZ-TIF2 expressing U937 cells after 
standardization to β tubulin levels used as a loading control. C. Expression of C/EBPβ 
RNA in RA treated U937 cells. Cells were treated with RA for 24 and 48 hours. 
RNA was extracted and RT-PCR was conducted as described in Experimental Proce-
dures. The fold-induction by RA was calculated as RA treated sample over non-
treated sample for 24 hours (open bars) and 48 hours (dark bars) of RA treatment. 
D. Fold-induction of CD11b RNA in RA treated U937 cells. Cells were treated with 
1 µM RA for 8 and 48 hours. RNA was extracted, real-time RT-PCR conducted, and 
fold-induction by RA calculated comparing the RA treated sample to the non-treated 
sample. Open and dark bars, 8 and 48 hours of RA treatment respectively. E. Per-
centage of CD11b positive U937 cell after RA treatment. Cells were treated with 1 
µM RA for 72 hours and were stained with APC-conjugated anti CD 11b antibody 
(eBiosciences, San Diego, CA.) After washing, the stained cells were analyzed by flow 
cytometry (BD Biosciences, Franklin Lakes, NJ) and the percentage of CD11b posi-
tive cells calculated with FlowJo 6.3 software. Top and middle panel, a representative 
histograph of CD11b stained U937 cells stably transfected with pcDNA3 (top) and 
MOZ-TIF2 (middle). Y-axis, % cell number and X-axis, APC stain intensity. The hori-
zontal line scale represents the range of CD11b positive cells. The dashed and solid 
lines represent basal and RA treated U937 cells, respectively. The number above the 
line scale indicates percentage of CD11b positive cells after treatment with RA. Bot-
tom panel, percentage of CD11b positive U937 cells stably transfected with control 
(pcDNA3), MOZ-TIF2 (MT2), MT2 del 82–892, and MT2 del CID. The experiment 
was conducted in triplicates with the open bars representing the basal level of 
CD11b positive cells and the dark bars representing the level of CD11b after RA 
treatment. Double stars represent a significant difference at P < 0.01 by a two tailed 
Student T- test compared to the RA treated U937 cells with MT2-2. The percentage 
inhibition cited in the text was calculated from the amount of RNA or protein 
expressed in MOZ-TIF2 expressing cells compared to that in pcDNA-transfected 
control cells in presence of RA subtracted from 100%.Molecular Cancer 2007, 6:51 http://www.molecular-cancer.com/content/6/1/51
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of the MOZ portion or CID domain increased the number
of CD 11b positive cells to 80% of control cells.
Discussion
Previously, MOZ-TIF2 has been shown using reporter sys-
tems to repress both RA and PPAR gamma receptor medi-
ated transcription in U937 cells and p53 mediated
transcription in p53 null cell lines [41]. In the investiga-
tions reported here, we used ER- and AR-mediated tran-
scription reporter systems as models to study the effect of
MOZ-TIF2 on nuclear receptor signaling in CV-1 and
HEK293 cells, lines that have been widely used for the
investigation of nuclear receptor signaling. We found that
the MOZ-TIF2 fusion inhibited both ER and AR-mediated
transcription compared both to the pcDNA3 vector alone
and to MOZ and TIF2. The transcription inhibition by
MOZ-TIF2 in ER mediated transcription occurred in both
basal and estradiol-stimulation conditions. In the AR-
mediated transcription system, MOZ-TIF2 exerted a
strong suppression only of DHT induced transcription.
The differences in the effect of MOZ-TIF2 on basal tran-
scription in the ER and AR reporter systems may result
either from MOZ-TIF2 exerting a ligand independent
effect on the ERE binding element or promoter specific
effects similar to those reported for other hormone recep-
tors [46]. We also observed that in the AR-mediated tran-
scription system TIF2 decreased the response to DHT
though to a far lesser extent than MOZ-TIF2. The effect of
TIF2 again suggests promoter specific effects which may
be related to the previously described interactions
between LXXLL motifs of TIF2 with the ligand-binding
domain of the androgen receptor that allowed for nega-
tive regulation [47]. Some support for this explanation
comes from the observation that TIF2 inhibits DHT stim-
ulation of the PSA promoters though to a lesser degree
than MOZ-TIF2. In addition, we demonstrated that
expression of MOZ-TIF2 in U937 cells at levels similar to
that of patient's leukemic blasts inhibited the response of
endogenous genes, C/EBPβ and CD11b to RA, suggesting
that MOZ-TIF2 could decrease nuclear receptor-mediated
transcription in vivo.
To explore the universal inhibition of MOZ-TIF2 in
nuclear receptor-mediated transcription, we tested the
effect of MOZ-TIF2 on ER mediated transcription in K562
and HEK 293 cells. Interestingly, the inhibition by MOZ-
TIF2 of basal and ligand-dependent transcription in an ER
reporter system was not as great as observed in CV-1 cells,
indicating that the repression by MOZ-TIF2 of nuclear
receptor-mediated transcription may be cell-dependent.
Cell specific effects are supported by the observation that
MOZ-TIF2 repressed a p53-responsive reporter plasmid in
CV-1 and HEK293 cells to a far lesser extent (data not
shown) than has been reported in SaOs2 cells [41].
The MYST domain in MOZ has HAT activity and the
domain is retained in the MOZ-TIF2 fusion. In our sys-
tems, a mutation in the acetyl-CoA binding site (G657D)
of the MYST domain, which is known to abolish HAT
activity [40], did not abrogate MOZ-TIF2-mediated
repression of ER-mediated transcription and had only a
slight effect on AR-mediated transcription (data not
shown). These results imply that HAT activity of the MOZ
portion has no functional significance in nuclear receptor
mediated transcription by MOZ-TIF2 fusion protein. The
non-essential role of HAT activity in the MOZ fusion pro-
tein has been observed previously as the abolishment of
HAT activity in the MOZ-CBP fusion protein did not sig-
nificantly change AML1-mediated transcription activity
and the same mutation in MOZ-TIF2 was not required for
transformation of myeloid cells while C2HC nucleosome
recognition motif was essential for MOZ-TIF2 transforma-
tion [17,40].
In nuclear receptor-mediated transcription, protein
acetylation may be provided by recruitment of the coacti-
vators, CBP/p300 via the p160 SRC family [48,49]. CBP/
p300 are universal transcription coactivators with HAT
activity [50,51] that participate in multiple transcriptional
events mediated by viral oncoproteins, hematopoiesis-
related transcription factors, tumor suppressors, and
nuclear receptors through the regulation of histone
acetylation and interaction with the basal transcriptional
machinery [52-55]. CBP/p300 also contributes to the
acetylation of non-histone proteins, such as Rb, E2F, and
P53 and regulates cell growth and differentiation. Both
deficient CBP/p300 and mutated CBP/p300 are relevant
to the hematopoietic malignancies and solid tumors [56-
59]. In the MOZ-TIF2 fusion, CID, a CBP interacting
domain in TIF2 portion, is retained and this domain is
required for inhibition of RA and PPRAγ receptor-medi-
ated transcription and for leukemogenesis [41]. We dem-
onstrated that the deletion of this domain in MOZ-TIF2
removed the repression of ER and AR-mediated transcrip-
tion and partially reversed the response of endogenous
CD11b to RA. Furthermore, the mutations in two leucine-
rich repeats of the CID showed a similar effect as the dele-
tion. In contrast, the deletion of CID from TIF2 sup-
pressed the ER and AR-mediated transcription suggesting
that the binding of MOZ-TIF2 to CBP/p300 played a
direct role in inhibition of ER and AR-mediated transcrip-
tion by MOZ-TIF2. The expression level of CBP in cells has
been reported as an important factor in the inhibition of
p53-mediated transcription by MOZ-TIF2 [41]. However,
in the nuclear receptor-mediated transcription model
increased expression of CBP did not alter the inhibition of
ER-mediated transcription by MOZ-TIF2. In contrast, co-
expressed wild type TIF2 interfered with MOZ-TIF2 inhi-
bition suggesting that TIF2 may be an important compet-Molecular Cancer 2007, 6:51 http://www.molecular-cancer.com/content/6/1/51
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itor and cellular levels of TIF2 could modify inhibition of
nuclear receptor mediated transcription.
By co-immunoprecipitation we demonstrated that ER,
CBP, and MOZ-TIF2 were in same protein complex. It is
known that in nuclear receptor-mediated transcription
TIF2 recruits CBP/P300 via CID [60]. Therefore, the inter-
action between CBP and MOZ-TIF2 could be explained by
the binding of the CID moiety in the TIF2 portion of the
fusion protein. However, we found that CBP was also co-
precipitated by wild type MOZ, which suggested that the
MOZ portion of MOZ-TIF2 could interact with CBP
directly. In support of the participation of MOZ, the phys-
ical interaction between the MOZ portion (amino acids
1–759) of MOZ-TIF2 and the C-terminal of CBP (amino
acids 1680 to 2441) was shown in GST pull-down experi-
ments. The mapping of the CBP binding region in the
MOZ N-terminus suggests multiple CBP binding sites.
Analysis of the MOZ protein sequence shows a CBP bind-
ing sequence, FX(D/E)XXXL, is located in the MYST
domain at amino acids 600–606. In addition, four bind-
ing consensus-like motifs, XX (D/E) XXXL, are in the PHD
domain of MOZ (amino acids 1–253) and three XX (D/E)
XXXL motifs are located in the MYST domain. It has been
shown that any single substitution in FX (D/E) XXXL was
not able to block the binding of E1A to CBP [45]. The
MOZ portion binding sites in CBP were in the CH3
domain which contains a transcriptional adapter motif
(TRAM) (amino acids 1811–1822) which binds competi-
tively to p53, E1A, E2F, and overlaps with the binding
sites for mdm2, myoD, and P/CAF. The analysis of solu-
tion structure supports the binding ability of this domain
[61]. However, our results suggest that there is/are some
CBP binding site(s) even beyond the PHD and MYST
domains because a MOZ-TIF2 fragment with the deletion
of both domains still bound to CBP. Interestingly, each
CBP binding site in MOZ portion may be of similar
importance in the suppression of nuclear hormone-stim-
ulated transcription by MOZ-TIF2.
Co-activation of ER and AR by p160 SRC family members
is through two sites of interaction. One interaction occurs
between the NID of the p160 proteins and the AF2
domain of ER and AR. The other interaction occurs
between the C-terminus of p160 proteins and the AF1
domain in N-terminus of ER and AR and within AR the
later interaction is stronger than former [62-66]. In the
MOZ-TIF2 protein, the NID of TIF2 has been eliminated
by the chromosomal translocation. Loss of this domain
will change the interaction of MOZ-TIF2 with ER and AR.
In our study, although ER was co-immunoprecipated with
MOZ-TIF2 the ER level was almost half that which was
pulled down by wild type TIF2. It seems that MOZ-TIF2
may participate in the transcriptional complex of ER in a
way different from wild type TIF2. There are two alterna-
tive ways for MOZ-TIF2 to interact with ER: MOZ-TIF2
could interact with the AF1 domain of ER or MOZ-TIF2
could interact through other complex members such as
CBP which has been shown to bind directly to ER [67,68].
Conclusion
Our work conclusively suggests that MOZ-TIF2 as a biden-
tate CBP binding protein competes with wild type TIF2 in
ER and AR mediated transcription. The aberrant binding
to ER or AR and CBP by MOZ-TIF2 disorders the complex
for receptor signaling and may bring about abnormal
acetylation of histone and non-histone proteins or cause
other aberrant modifications, which finally lead to the
inhibition of transcription activation by liganded ER and
AR. In addition, the MOZ portion of the fusion protein
not only determines the localization of MOZ-TIF2 within
the cell but also contributes to the inhibition by MOZ-
TIF2 of nuclear receptor activation.
Methods
Plasmids
The MOZ-TIF2 fusion cDNA was constructed by the join-
ing of the PCR-created fusion fragments to the MOZ part-
ner at a Hind3 site and the TIF2 partner at a Sac1 site in
pBluescript KS phagemid vector. The fusion cDNA was
subsequently subcloned into the pcDNA 3.1A (Invitro-
gen, Carlsbad, CA), pEGFP (BD Biosciences Clontech,
Palo Alto CA), pGEX (Amersham Pharmacia Biotech, Pis-
cataway, NJ), and pET-30 (Novagen, Madison WI). The
luciferase reporter plasmid containing two ER binding ele-
ments plus a TK minimal promoter (Vit TKSL) was a kind
gift from Dr. James Mathis. The luciferase reporter plas-
mid driven by the long promoter/enhancer (PL) carrying
the sequence between -6480 and +12 nucleotides of PSA
(prostate specific antigen) or driven by the core promoter
(PS) from -648 to +12 nucleotides of PSA was a gift from
Dr. Stephen P. Balk [69,70].
RNA isolation and RT-PCR
RNA was isolated from transduced or transfected cells and
leukemic blasts of patients with TRI Reagent (Molecular
Research Center, Inc., Cincinnati OH). PCR primers were
designed to yield amplicons ranging in length from 270 to
776 bp with Tm between 52.5 and 60.5°C, with most of
the primer sets having an optimum Tm of 56–57°C
(Table 1). One microgram of RNA was reversed tran-
scribed with Superscript™ II, RNase H- Reverse RT-PCR as
previously described [71]. Briefly, the RT mixture was
diluted 10–1000 fold in water so that amplicons of differ-
ent abundances could be amplified in parallel with the
same number of cycles. Based on the abundance of each
amplicon in preliminary analyses, target sequences in 1
µL of the appropriate dilution of the cDNA reaction were
amplified in 10 µL reactions containing 0.25 units of Taq,
2 pmol each of the sense and antisense primers in PCRMolecular Cancer 2007, 6:51 http://www.molecular-cancer.com/content/6/1/51
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buffer, 62.5 µM of each dNTP, and 0.05 µL [α-32P]dCTP.
Control PCR reactions using no added DNA template and
using no RT were done as sets after the cDNA amplifica-
tions were complete. Following electrophoresis through
1.5% Tris-Borate-EDTA (TBE) agarose gels, the amplicons
were transferred by electroblotting to GeneScreen Plus
nylon membranes (Dupont, Boston, MA), the images
detected on a Molecular Dynamics PhosphorImager, and
analyzed by volume integration with the ImageQuant
software. The expression levels for each of the genes were
normalized to the GAPDH expression. In some experi-
ments, regular PCR or real-time PCR was conducted with-
out [α-32P]dCTP.
Mutation and deletion
Both point and deletion mutations in the MOZ-TIF2
fusion cDNA were constructed with QuikChange® Site-
Directed Mutagenesis Kit (Stratagene, La Jolla CA). The
primers used for the deletion and mutation are listed in
Table 2. All mutations were verified by sequencing.
Cell culture and transfection
HEK293 and CV-1 cells were grown in DMEM (Mediatech
Cellgro, Herndon VA) containing 10% fetal bovine serum
(FBS). K562 AND U937 cells were grown in RPMI1640
with 10% FBS. Transfections of HEK293 and CV-1 cells
were done with Lipofectamine Plus (Invitrogen, Carlsbad
CA) and of K562 cells with FuGENE 6 transfection reagent
(Roche Applied Science, Indianapolis IN). U937 cells
were transfected by electroporation. Transiently trans-
fected cells were harvested 24–48 hours after transfection
as indicated for the specific studies. Stable transfected cells
were selected with G418 for 2–3 weeks.
Subcellular location by fluorescent microscopy and 
immunofluorescence staining
To determine the subcellular location of MOZ-TIF2, a GFP
fusion of MOZ-TIF2 was expressed in HEK293, K562, and
CV1 cells by transient transfection. After 24 hours the cells
were fixed in 1% paraformaldehyde and examined by epi-
fluorescence microscopy. To examine localization of the
MOZ-TIF2 protein and protein products of various MOZ-
TIF mutations in living cells, cells were cultured in 6-well
plates. After 24 hours of transfection, cells were stained
with DRAQ5™ (AXXORA, LLC, San Diego, CA) and
images collected on a laser scanning confocal microscope
(Bio-Rad Laser Scanning System Radiance 2000/Nikon
Eclipse TE300 microscope) with LaserSharp 2000 soft-
ware (Bio-Rad, Hercules, CA). To observe co-localization
between endogenous MOZ and CBP, HEK293 and Hela
cells were fixed in 1% paraformaldehyde, blocked with
3% bovine serum albumin in PBS, and incubated with
antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA) against MOZ (N-19, sc-5713) at 1:100 and CBP (C-1,
sc-7300) at 1:200. Nuclei were counterstained with TO-
PRO®-3 iodide (In Vitrogen-Molecular Probes, Carisbad,
CA) and images collected as above.
Luciferase assay
CV1 and HEK 293 cells were transfected by Lipofectamine
Plus in 24-well plates with 350 to 400 ng of luciferase
reporter plasmids, 100 ng of expression plasmids of MOZ,
MOZ-TIF2, TIF2, MOZ-TIF2 mutants, and 50 ng of estro-
gen or androgen receptor expression vector. After 36 hours
of induction with 50 nM of estradiol (E) or 5α-dihy-
drotestosterone (DHT) in medium containing 10% dex-
tran-charcoal-stripped fetal calf serum, cells were lysed
with Cell Culture Lysis Reagent (Promega, Madison WI)
and the luciferase assay was performed in a Monolight®
Table 1: The primer sets applied in PCR
Gene bp upstream primer downstream primer
MOZ 481 CGT CGC TAC AGT GAG GGT GA G TTT TCG CAA AAG AGA TAC TGG CT
MOZ 577 CGT CGC TAC AGT GAG GGT GA A GTG GAT TGG TTT GCG GCT C
p300 361 GA GCA CCC GTT GGA CTT GGA GA GGG CAC ACT GGC ATT TTC A
CBP 399 GAG GTT TTT GTC CGA GTG GTG G TGG GTG GCA ATG GAA GAT GTA A
PCAF 309 CA AAC GCA GGG AGC AGC AGT T GTT TGG TTT CTG GTT GAG GGA
PCAF 384 CA AAC GCA GGG AGC AGC AGT T GTA TTC TTT TGG CAT TCG GGG
SRC1 300 GG CAG CAA GGA GCG ATA GGA G GGT TCC ATC TGC TTC TGT TTT G
TIF2 638/428 CG GTG AGC CCC AAG AAG AAA CCG AGA AGC ACT GTT ACC AAT CAT
TIF2 270/60 GGA GCC CAG AAA ACA GCA CT CCG AGA AGC ACT GTT ACC AAT CAT
TIF2 578/368 GGA GCC CAG AAA ACA GCA CT GC AAA AGA CGC CTG GTC TAT
MOZ/TIF2 776 CGT CGC TAC AGT GAG GGT GA GC AAA AGA CGC CTG GTC TAT
MOZ/TIF2 468 CGT CGC TAC AGT GAG GGT GA CCG AGA AGC ACT GTT ACC AAT CAT
NCOA3 395 C CAA GCA GCA GCA TCT AAC CAA C G TCC CTG AAG ATG AAA GCC TCC T
CD11b 73 AGT TGC CGA ATT GCA TCG A GGC GTT CCC ACC AGA GAG A
C/EBP b 225 CCT CGC AGG TCA AGA GCA A ACA AGT TCC GCA GGG TGC T
Gene, gene symbol. bp, the PCR fragment length in base pairs.Molecular Cancer 2007, 6:51 http://www.molecular-cancer.com/content/6/1/51
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2040 luciferase luminometer by adding 10 µl of cell lysate
to 100 µl of reaction mix consisting of 1 × salt buffer with
pH 7.8 (20 mM of Tricine, 1.07 mM (MgCO3)4Mg (OH)2·
5H2O, 2.67 mM MgSO4, 0.2 mM EDTA, 530 µM ATP,
33.3 µM DTT, 270 µM coenzyme A, and 470 µM potas-
sium luciferin. The luciferase activity was standardized for
transfection efficiency with β-galactosidase activity. All
experiments were performed at least in quadruplicate and
repeated at least twice.
Co-immunoprecipitation and immunoblotting
HEK293 cells were transfected either with EGFP or a His-
tag fusion of MOZ, MOZ-TIF2, or TIF2. In some experi-
ments, a vector expressing the human estrogen receptor
was co-transfected. Cell lysates were prepared with indi-
vidual homogenizers in lysis buffer (50 mM NaCl, 5 mM
KCl, 1 mM EDTA, 20 mM HEPES, pH 7.6, 10% glycerol,
and protease inhibitor cocktails (Roche Applied Science,
Indianapolis IN)). Immunoprecipitation was conducted
with antibodies against His-tag or EGFP. Briefly, 2 µg of
agarose-conjugated anti-His-tag (Santa Cruz Biotechnol-
ogy, Santa Cruz CA) or anti-GFP antibody (BD Bio-
sciences, Palo Alto CA) bound to protein A/G-agarose
(Santa Cruz Biotechnology, Santa Cruz CA) was added to
about 500 µg protein of cell lysate, incubated at 4°C over-
night with rotation, the precipitate collected by centrifu-
gation and washed with phosphate buffered saline (PBS)
containing 0.5 % NP-40. After the final wash, the pellet
was separated by SDS-PAGE and the western analysis con-
ducted with antibodies against CBP and estrogen receptor.
In some experiments, RIPA buffer was used to extract
whole cell protein for western analysis.
GST pull down assay
The GST fusion proteins were expressed with pGEX con-
structs containing designated cDNA fragments in BL21-
CodonPlus®(DE3)-RIL cells (Stratagene, La Jolla CA). The
expressed GST fusion protein was purified with the GST
Purification Module (Amersham Pharmacia Biotech, Eng-
land), fractionated by SDS-PAGE, and proteins detected
by staining with Coomassie Blue. To perform the GST pull
down affinity assay, [35S] Met-labeled proteins were pro-
duced with the Single Tube Protein® System 3 (Novagen,
Madison WI) from pET 30 vectors containing designated
cDNA fragments. The binding reaction was conducted
with 5 µl of in vitro-translated protein and 3–5 µg of GST
or GST fusion protein bound to Sepharose 4B beads in
200 µl binding buffer (50 Mm Tris-HCl, pH 8.0, 100 mM
NaCl, 0.3 mM DTT, 10 mM MgCl2, 10% glycerol, 0.1%
NP40). The reaction was performed at 4°C for 1 hour fol-
lowed by five washes of the beads with binding buffer,
separation of bound proteins by SDS PAGE followed by
autoradiography. In some experiments, non-isotope
labeled X-press-tagged proteins were used and proteins
pulled down by GST-fusion were examined by anti X-
press antibody (Invitrogen Co., Carisbad, CA).
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